Novo Nordisk A/S (NONOF)
| Market Cap | 304.96B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | n/a |
| EPS (ttm) | 3.40 |
| PE Ratio | 20.12 |
| Forward PE | 16.26 |
| Dividend | 1.66 (2.43%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 404 |
| Average Volume | 137,700 |
| Open | 65.95 |
| Previous Close | 66.48 |
| Day's Range | 65.95 - 70.00 |
| 52-Week Range | 55.28 - 149.55 |
| Beta | 0.22 |
| RSI | 43.16 |
| Earnings Date | Aug 6, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
‘Very obvious:’ Novo Nordisk may be illegally advertising Ozempic, says Spain’s health secretary
Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.
Novo Nordisk says WeightWatchers will sell Wegovy, announces US$299 price
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know . What...
Novo Nordisk taps WeightWatchers for Wegovy after exiting Hims & Hers deal
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Novo Nordisk ties up with WeightWatchers to sell Wegovy
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on ...
Eli Lilly to bring Mounjaro pen in India to rival Novo Nordisk’s Wegovy
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
Why Shares in Novo Nordisk Lost Weight Today
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatme...
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novo Nordisk A/S (“Novo N...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
After Its Biggest Drop Ever...Is HIMS A Buy?
HIMS just suffered the biggest single-day drop in its trading history… a HISTORIC 34.53% pull back. And CEO Andrew Dudum isn't backing down. Hims & Hers Health (NYSE: HIMS) After $NVO Novo Nordisk ab...
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
The Best European Stocks to Buy
European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) investors concerning the Company's...
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Compan...
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
Novo Nordisk’s Wegovy debuts in India: How it works, who it’s for, and how much it costs
Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targetin...
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth darling Hims & Hers Health Inc (NYSE: HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE: NVO) ended their relationship – and it wasn't amicable. But is the plunge...